Phase II study of tepotinib plus gefitinib (TEP plus GEF) in MET-positive (MET plus )/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)

被引：0

作者：

Cheng, Y. ^{[1
]}

Zhou, J. ^{[2
]}

Lu, S. ^{[3
]}

Zhang, Y. ^{[4
]}

Zhao, J. ^{[5
]}

Pan, H. ^{[6
]}

Chen, Y-M. ^{[7
]}

Chian, C-F. ^{[8
]}

Bruns, R. ^{[9
]}

Johne, A. ^{[10
]}

Scheele, J. ^{[10
]}

Wu, Y-L. ^{[11
,12
]}

机构：

[1] Jilin Prov Canc Hosp, Med Oncol, Changchun, Jilin, Peoples R China

[2] Zhejiang Univ, Dept Resp Dis, Thorac Dis Ctr, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China

[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China

[4] Zhejiang Canc Hosp, Thorac Med Oncol, Hangzhou, Zhejiang, Peoples R China

[5] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Dept Thorac Med Oncol, Beijing, Peoples R China

[6] Zhejiang Med Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China

[7] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan

[8] Triserv Gen Hosp, Dept Internal Med, Natl Def Med Ctr, Taipei, Taiwan

[9] Merck KGaA, Biostat, Darmstadt, Germany

[10] Merck KGaA, Global Clin Dev, Darmstadt, Germany

[11] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China

[12] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1377O

引用

页码：493 / 493

页数：1